Li Ka-shing funds Asia's first non-invasive kidney tumour trials in Hong Kong

Hong Kong will host Asia's first clinical trials of histotripsy, a non-invasive ultrasound-based tumour treatment, funded by the Li Ka Shing Foundation across three private hospitals. The technology, already used elsewhere, is being introduced to the region for the first time, with 30 patient slots. This marks a notable expansion of advanced medical technology in Asia, though efficacy and adoption remain to be seen.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works